Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 20, 2024
Discovery & Translation

Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more

BioCentury’s roundup of translational innovations
BioCentury | May 29, 2021
Targets & Mechanisms

New life for EGFR at ASCO21

ASCO21 abstracts highlight opportunities for new EGFR-targeting agents and combos to fill holes left by TKIs
BioCentury | Jun 24, 2019
Tools & Techniques

A new flavor of allosteric modulators: synthetic proteins

Why a Brandeis-NYU team turned to proteins, rather than small molecules, for allosteric modulators
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

BioCentury | Jun 28, 2018
Distillery Techniques

Disease models

BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

How Lilly’s new R&D head aims to beef up the pharma’s first-in-class cache
Items per page:
1 - 10 of 74